Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | GAA | P10253 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | GLA | P06280 | 1/20 | 0.58 |
| ▸ | THRB | P10828 | 1/20 | 0.58 |
| ▸ | BLM | P54132 | 1/20 | 0.58 |
| ▸ | CASP6 | P55212 | 1/20 | 0.58 |
| ▸ | GFER | P55789 | 1/20 | 0.58 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.50 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.50 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.50 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | F2 | P00734 | 2/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7143263 | 0.84 | KMT2A (0.46) | TDP1MAPTGAAKDM4EGLA | |
| SCHEMBL5516916 | 0.83 | GAA (0.58) | TDP1MAPTGAAKDM4EGLA | |
| SCHEMBL11675308 | 0.81 | TDP1 (0.56) | TDP1MAPTGAAKDM4EGLA | |
| SCHEMBL7917161 | 0.81 | TDP1 (0.56) | TDP1MAPTGAAKDM4EGLA | |
| SCHEMBL27486662 | 0.81 | LIPE (0.54) | MAPTKDM4EALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL6613749 | 0.81 | LMNA (0.57) | TDP1MAPTGAAKDM4EPRSS1 | |
| SCHEMBL27853710 | 0.81 | CA1 (0.60) | MAPTGAAPARP10ALDH1A1RAB9A | |
| SCHEMBL721196 | 0.80 | SLC1A3 (0.53) | TDP1MAPTGAAKDM4ETHRB | |
| SCHEMBL15333894 | 0.79 | MEN1 (0.42) | TDP1MAPTGAAKDM4EGLA | |
| SCHEMBL16280936 | 0.79 | MAPT (0.86) | TDP1MAPTGAAKDM4EGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7250435-B2 | Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-07-31 | — | — | US | disclosed |
| US-20050261353-A1 | Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2005-11-24 | — | — | US | disclosed |
| CN-1553900-A | Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents | ��ʱ��ʩ����ҩ��˾ | 2004-12-08 | — | — | CN | disclosed |
| EP-1414804-A1 | ACYLSEMICARBAZIDES AND THEIR USE AS CYCLIN DEPENDENT KINASE (CDK) INHIBITORS | Bristol-Myers Squibb Pharma Company (US) | 2004-05-06 | — | — | EP | disclosed |
| US-20040048844-A1 | Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-03-11 | — | — | US | disclosed |
| US-6593356-B2 | The present invention relates to the synthesis of a new class of indeno(1,2-c)pyrazol-4-ones of formula (I): that are potent inhibitors of the class of enzymes known as cyclin dependent kinases, which relate to the catalytic subunits cdk1-7 and the | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-07-15 | — | — | US | disclosed |
| US-20030073686-A1 | Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-04-17 | — | — | US | disclosed |
| WO-2002034721-A1 | ACYLSEMICARBAZIDES AND THEIR USE AS CYCLIN DEPENDENT KINASE (CDK) INHIBITORS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2002-05-02 | — | — | WO | disclosed |
| US-6291504-B1 | POTENT INHIBITORS OF THE CLASS OF ENZYMES KNOWN AS CYCLIN DEPENDENT KINASES | DUPONT PHARMACEUTICALS COMPANY | 2001-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073686-A1 | Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents | CDK1, CCNA1, CDK17 | TDP1 1458/4885MAPT 4802/4885GAA 1553/4885 |
| US-20050261353-A1 | Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents | CDK1, CDK17, CDK7 | TDP1 2196/4885MAPT 4763/4885GAA 993/4885 |
| US-20040048844-A1 | Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents | CDK1, CCNA1, CDK17 | TDP1 1458/4885MAPT 4802/4885GAA 1553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.